Charles River Laboratories International Revenue and Competitors

Boston, MA USA

Location

$1.5B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Charles River Laboratories International's estimated annual revenue is currently $3.4B per year.(i)
  • Charles River Laboratories International's estimated revenue per employee is $190,661
  • Charles River Laboratories International's total funding is $1.5B.
  • Charles River Laboratories International's current valuation is $17.9B. (January 2022)

Employee Data

  • Charles River Laboratories International has 17990 Employees.(i)
  • Charles River Laboratories International grew their employee count by 2% last year.

Charles River Laboratories International's People

NameTitleEmail/Phone
1
Co-Founder - Retrogenix | A Charles River CompanyReveal Email/Phone
2
Executive Director, Global Sales OperationsReveal Email/Phone
3
Executive Director SalesReveal Email/Phone
4
Corporate VP, Global Discovery Business DevelopmentReveal Email/Phone
5
Corporate VP, NA Research Models, Client RelationsReveal Email/Phone
6
Executive Director, North American RMS Sales & MarketingReveal Email/Phone
7
Corporate VP, Finance, Corporate ControllerReveal Email/Phone
8
Corporate VP Global Commercial GrowthReveal Email/Phone
9
Sr Corp VP Regulatory Affairs and ComplianceReveal Email/Phone
10
Corporate VPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$86.4M4308%N/AN/A
Add Company

What Is Charles River Laboratories International?

From our headquarters near Boston, MA, Charles River Laboratories\' 8,000 employees serve clients in more than 50 countries. We are a global provider of solutions that advance the drug discovery and development process. Our leading-edge products and services are designed to enable our clients to bring drugs to market faster and more efficiently. Backed by our rigorous, best-in-class procedures and our proven data collection, analysis and reporting capabilities, our products and services are organized into three categories spanning every step of the drug development pipeline: Research Models and Services, Preclinical Services, and Clinical Services.

keywords:N/A

$1.5B

Total Funding

17990

Number of Employees

$3.4B

Revenue (est)

2%

Employee Growth %

$17.9B

Valuation

N/A

Accelerator

Charles River Laboratories International News

2022-04-20 - How Does Charles River Laboratories Intl. Inc (CRL) Stock Rank on Wall Street Tuesday?

That average rating earns Charles River Laboratories Intl. Inc an Analyst Ranking of 72, which means it ranks higher than 72 of stocks,...

2022-04-19 - Charles River Laboratories Intl. Inc (CRL) is down -7.07% in a Week, Should You Accumulate?

Charles River Laboratories Intl. Inc also received an overall rating of 52, putting it above 52% of all stocks. Diagnostics & Research is ranked...

2022-03-30 - Charles River Laboratories Acquires Explora BioLabs

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading...

2021-10-13 - Charles Riv­er Lab­o­ra­to­ries has been on an ac­qui­si­tion spree. But Tues­day, it of­floaded two as­sets

Fol­low­ing a sum­mer filled with merg­ers and ac­qui­si­tions, Charles Riv­er Lab­o­ra­to­ries has di­vest­ed its re­search op­er­a­tions in Japan and a CD­MO site in Swe­den, en­gi­neer­ing two sep­a­rate deals ex­pect­ed to cut down $20 mil­lion in rev­enue. Tues­day, Charles Riv­er sold its ...

2021-06-07 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories International : Announces Long-Term Solar Contract for North American Operations

Commits to sourcing 100% renewable electricity and reducing 50% of greenhouse gas emissions from facilities by 2030 WILMINGTON, Mass.--(BUSINESS WIRE)--Jun. 7, 2021-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a long-term solar energy contract to address the enti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15380M264067%N/A
#2
$5099.8M32902-4%N/A
#3
$8620.9M42890N/AN/A